Your browser is no longer supported. Please, upgrade your browser.
Settings
AKRX Akorn, Inc. daily Stock Chart
AKRX [NASD]
Akorn, Inc.
Index- P/E- EPS (ttm)-3.84 Insider Own2.00% Shs Outstand129.62M Perf Week12.64%
Market Cap531.44M Forward P/E14.19 EPS next Y0.29 Insider Trans4.22% Shs Float91.05M Perf Month51.29%
Income-482.00M PEG- EPS next Q-0.04 Inst Own76.80% Short Float14.74% Perf Quarter-14.23%
Sales662.90M P/S0.80 EPS this Y-683.30% Inst Trans1.97% Short Ratio6.96 Perf Half Y17.14%
Book/sh2.07 P/B1.98 EPS next Y293.30% ROA-31.60% Target Price6.30 Perf Year-69.36%
Cash/sh1.38 P/C2.98 EPS next 5Y- ROE-111.20% 52W Range2.34 - 13.41 Perf YTD20.94%
Dividend- P/FCF- EPS past 5Y-55.30% ROI-28.10% 52W High-69.43% Beta1.98
Dividend %- Quick Ratio0.40 Sales past 5Y16.90% Gross Margin30.80% 52W Low75.21% ATR0.31
Employees2191 Current Ratio0.50 Sales Q/Q-6.70% Oper. Margin-64.10% RSI (14)68.40 Volatility8.67% 9.89%
OptionableYes Debt/Eq3.17 EPS Q/Q-26.10% Profit Margin-72.20% Rel Volume2.05 Prev Close3.67
ShortableYes LT Debt/Eq0.00 EarningsAug 01 BMO Payout- Avg Volume1.93M Price4.10
Recom2.70 SMA2030.64% SMA5023.82% SMA2008.02% Volume3,944,771 Change11.72%
Mar-20-19Initiated SunTrust Hold
Oct-17-18Upgrade Piper Jaffray Neutral → Overweight
Jul-25-18Reiterated RBC Capital Mkts Sector Perform $25 → $27
Apr-25-17Downgrade Piper Jaffray Overweight → Neutral
Apr-25-17Downgrade Jefferies Buy → Hold
Apr-25-17Downgrade Gabelli & Co Buy → Hold
Mar-10-17Reiterated WallachBeth Hold $22 → $25
Dec-01-16Initiated Goldman Sell
Nov-07-16Downgrade WallachBeth Buy → Hold $40 → $22
Nov-07-16Downgrade BofA/Merrill Buy → Underperform
Nov-04-16Downgrade RBC Capital Mkts Outperform → Sector Perform $37 → $24
Sep-15-16Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated WallachBeth Buy $39 → $40
Aug-05-16Downgrade Deutsche Bank Buy → Hold $33 → $33
Aug-02-16Downgrade Raymond James Outperform → Mkt Perform
Mar-18-16Reiterated Deutsche Bank Buy $40 → $33
Feb-12-16Reiterated RBC Capital Mkts Outperform $52 → $37
Dec-02-15Upgrade Nomura Neutral → Buy
Sep-29-15Initiated Nomura Neutral
Sep-09-15Initiated JMP Securities Mkt Perform
Aug-26-19 01:35PM  Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15% GlobeNewswire +8.52%
Aug-14-19 03:30PM  Is Akorn (NASDAQ:AKRX) A Risky Investment? Simply Wall St. -7.12%
Aug-07-19 10:30PM  Edited Transcript of AKRX earnings conference call or presentation 1-Aug-19 1:00pm GMT Thomson Reuters StreetEvents
Aug-02-19 07:24AM  Akorn (AKRX) Q2 2019 Earnings Call Transcript Motley Fool -5.22%
Aug-01-19 08:55AM  Akorn (AKRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
Jul-29-19 11:33AM  Penny Stocks to Buy Using Technical Analysis for August 2019 Investopedia
Jul-25-19 10:33AM  Analysts Estimate Akorn (AKRX) to Report a Decline in Earnings: What to Look Out for Zacks -6.78%
Jul-11-19 04:32PM  Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call GlobeNewswire -5.57%
Jun-28-19 07:00AM  Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5% GlobeNewswire
Jun-27-19 11:20AM  Did Hedge Funds Drop The Ball On Akorn, Inc. (AKRX) ? Insider Monkey +7.29%
Jun-25-19 11:00AM  Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues Benzinga
10:32AM  Akorn gets FDA warning letter for another manufacturing plant Reuters
09:41AM  Akorn Files Complaint on Fresenius' Canceled Bid Investopedia
08:17AM  Drugmaker Akorn Receives FDA Warning Letter Regarding N.J. Facility TheStreet.com
08:08AM  UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant Reuters
07:44AM  Generics maker Akorn receives warning letter from the FDA relating to NJ facility MarketWatch
07:35AM  Akorn Receives FDA Warning Letter GlobeNewswire
Jun-14-19 07:01AM  How Many Akorn, Inc. (NASDAQ:AKRX) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
May-30-19 07:59AM  Akorn to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire
May-21-19 07:40AM  The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails Benzinga +5.02%
May-20-19 04:05PM  Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1% GlobeNewswire
08:01AM  Akorn to Present at the RBC Capital Markets Healthcare Conference GlobeNewswire
May-16-19 01:08AM  Edited Transcript of AKRX earnings conference call or presentation 7-May-19 2:00pm GMT Thomson Reuters StreetEvents
May-12-19 09:49PM  Heres What Hedge Funds Think About Akorn, Inc. (AKRX) Insider Monkey
May-08-19 09:24AM  Akorn (AKRX) Q1 2019 Earnings Call Transcript Motley Fool +29.58%
May-07-19 08:35AM  Akorn (AKRX) Reports Q1 Loss, Tops Revenue Estimates Zacks +17.16%
07:24AM  Akorn: 1Q Earnings Snapshot Associated Press
07:05AM  Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance GlobeNewswire
Apr-24-19 09:14AM  Introducing Akorn (NASDAQ:AKRX), The Stock That Tanked 89% Simply Wall St.
Apr-22-19 07:00PM  Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX) Business Wire +7.94%
03:00PM  FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
02:27PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc. GlobeNewswire
12:58PM  Here's Why Akorn Stock Rose as Much as 14.4% Today Motley Fool
11:09AM  DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:58AM  FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
09:28AM  Akorn Receives 2 Generic Nose Spray Approvals Benzinga
Apr-19-19 06:00PM  3-Day Deadline Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
05:36PM  Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI GlobeNewswire
Apr-18-19 05:00PM  Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5% GlobeNewswire -5.14%
04:05PM  Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) GlobeNewswire
01:47PM  APRIL 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. AKRX GlobeNewswire
01:40PM  4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:51AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX GlobeNewswire
10:57AM  AKRX, HIIQ & AMRN - Class Action Deadline Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-17-19 08:41PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc. GlobeNewswire -5.50%
Apr-16-19 04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX ACCESSWIRE
10:57AM  AKRX, HIIQ & AMRN - Class Action Notice Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-15-19 05:31PM  AKORN APRIL 22nd DEADLINE: Rosen Law Firm Reminds Akorn, Inc. Investors of Important Deadline in Securities Class Action Lawsuit Filed by the Firm AKRX GlobeNewswire
01:56PM  Akorn to Report First Quarter 2019 Financial Results and Host Conference Call GlobeNewswire
10:20AM  Block & Leviton LLP Reminds Shareholders of Important Deadlines: TAP, AKRX, SYNH, CTL GlobeNewswire
08:45AM  Options Traders Expect Huge Moves in Akorn (AKRX) Stock Zacks
Apr-12-19 03:30PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm ACCESSWIRE
03:00PM  AKRX, HIIQ & AMRN - Class Action Reminder Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
09:55AM  AKRX, HIIQ & AMRN - Class Action Update Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-11-19 03:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX ACCESSWIRE
Apr-10-19 10:21PM  AKRX ALERT: Zhang Investor Law Reminds Investors of April 22 Deadline in Securities Class Action Lawsuit Against Akorn, Inc. AKRX GlobeNewswire
Apr-09-19 08:31PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline - AKRX PR Newswire
10:48AM  Class Action Reminder - AKRX, HIIQ & AMRN Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-08-19 05:27PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In AKRX, UMC, CAG or CNDT To Contact The Firm GlobeNewswire
03:05PM  APRIL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:05PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. - AKRX ACCESSWIRE
Apr-07-19 09:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline  AKRX GlobeNewswire
Apr-05-19 03:00PM  Class Action Reminder AKRX, HIIQ & AMRN Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
10:46AM  Class Action Update - AKRX, HIIQ & AMRN Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-04-19 03:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX ACCESSWIRE
10:45AM  Bronstein, Gewirtz & Grossman, LLC Class Action - AKRX, HIIQ & AMRN ACCESSWIRE
Apr-03-19 07:04PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm ACCESSWIRE
12:00AM  Some drug companies are still imposing triple-digit price rises Financial Times
Apr-02-19 05:34PM  AKORN CLASS ACTION NOTICE: Rosen Law Firm Reminds Akorn, Inc. Investors of Important April 22nd Deadline in Securities Class Action Lawsuit Filed by the Firm AKRX GlobeNewswire -5.34%
05:25PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm Business Wire
03:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX ACCESSWIRE
03:24PM  Block & Leviton LLP Reminds Shareholders of Important Deadlines: TAP, AKRX, SYNH, CTL GlobeNewswire
Apr-01-19 11:35AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm ACCESSWIRE
Mar-29-19 08:15PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:33PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm Business Wire
01:54PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc. Business Wire
10:42AM  Class Action Notice AKRX, HIIQ & AMRN Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Mar-28-19 08:27PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc. (AKRX) Business Wire
04:12PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm GlobeNewswire
02:27PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline  AKRX GlobeNewswire
10:41AM  Class Action Update AKRX, HIIQ & AMRN Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Mar-27-19 05:15PM  Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Akorn, Inc. Investors Business Wire
04:39PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm GlobeNewswire
Mar-26-19 06:30PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akorn, Inc. Investors (AKRX) Business Wire
05:25PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX ACCESSWIRE
05:04PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm GlobeNewswire
10:46AM  AKRX DEADLINE ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Akorn, Inc. AKRX GlobeNewswire
10:40AM  Class Action Reminder - AKRX, HIIQ & AMRN Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Mar-25-19 02:13PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Akorn, Inc. Investors Business Wire
11:41AM  Block & Leviton LLP Reminds Shareholders of Important Deadlines: TAP, AKRX, SYNH, CTL GlobeNewswire
Mar-22-19 09:18PM  FINAL DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
05:10PM  AKRX INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Akorn, Inc. Investors Business Wire
Mar-21-19 06:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline AKRX GlobeNewswire
08:14AM  Block & Leviton LLP Reminds Shareholders of Important Deadlines: MU, AKRX, SYNH, CTL GlobeNewswire
07:00AM  Akorn Names Erislandy (Dandy) Dorado-Boladeres as Executive Vice President of Global Quality GlobeNewswire
Mar-20-19 09:09PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. AKRX GlobeNewswire
04:00PM  Class Action AKRX, AMRN & CAG Bronstein, Gewirtz & Grossman, LLC Update GlobeNewswire
02:50PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm Business Wire
09:48AM  Bronstein, Gewirtz & Grossman, LLC Class Action Update AKRX, AMRN & CAG ACCESSWIRE
Mar-19-19 08:30PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm PR Newswire
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MEYER STEVEN JDirectorAug 15Buy2.5010,00025,000183,154Aug 15 03:56 PM
MEYER STEVEN JDirectorAug 14Buy2.7010,00027,000173,154Aug 15 03:56 PM
WEINSTEIN ALAN DDirectorMay 31Buy3.9750,000198,500161,555Jun 04 04:22 PM
MEYER STEVEN JDirectorMay 29Buy3.7510,00037,500163,154May 30 08:30 AM
MEYER STEVEN JDirectorMay 20Buy4.1015,00061,500153,154May 22 08:46 AM
RAPPUHN TERRY ALLISONDirectorMay 13Buy4.0310,00040,30068,198May 15 08:43 AM
BONACCORSI JOSEPHEVP Gen Counsel & SecretaryDec 14Buy4.4825,000112,000541,283Dec 18 05:00 PM